Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $657,073.89 in Stock

27 Jan 2026, 23:06 by Michael Walen · The Markets Daily

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 6,831 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $657,073.89. Following the completion of the sale, the chief executive officer directly owned 169,402 shares in the company, valued at approximately $16,294,778.38. This trade represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Peetz also recently made the following trade(s):

On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $662,456.34.

Mirum Pharmaceuticals Stock Up 2.4%

MIRM traded up $2.35 on Tuesday, hitting $99.27. The company had a trading volume of 679,931 shares, compared to its average volume of 877,176. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $99.44. The stock has a fifty day simple moving average of $77.82 and a 200-day simple moving average of $71.21. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The firm has a market capitalization of $5.10 billion, a P/E ratio of -115.43 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same quarter last year, the firm posted ($0.30) earnings per share. The company’s revenue for the quarter was up 47.1% on a year-over-year basis. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

Positive Sentiment: Large director purchase — Director Patrick J. Heron bought 131,425 shares at ~$68.48 (Jan 23), increasing his ownership ~40%, signaling strong insider conviction. SEC Filing – Heron Form 4
Positive Sentiment: Price-target upgrade / bullish analyst note — HC Wainwright raised its price target to $130 and kept a Buy rating, issuing a very bullish long‑range EPS view (FY2030 EPS est. $6.16). That upgrade and forecast materially boosts upside expectations. The Fly – HC Wainwright Upgrade
Positive Sentiment: Acquisition closed — Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare‑disease portfolio and reinforcing growth/synergy narratives that investors favor in biotech M&A. Yahoo Finance – Bluejay Acquisition
Positive Sentiment: Momentum / new 52‑week high after upgrades — The stock hit a fresh 52‑week high following analyst upgrades and the above news, reinforcing momentum trading and positive sentiment among investors. American Banking News – 52‑Week High
Negative Sentiment: Executive selling — Several senior executives sold shares on Jan 26 (CEO Christopher Peetz sold 6,831 shares; COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe also sold smaller amounts). While transactions appear modest relative to market cap and include routine diversification, they can trigger short‑term selling pressure or worry some investors. SEC filings: CEO CEO Form 4, COO COO Form 4, CFO CFO Form 4, SVP SVP Form 4. Also summarized in a media note on insider selling: American Banking News – Insider Selling

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Stifel Nicolaus upped their target price on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Monday. Finally, TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $104.92.

View Our Latest Research Report on Mirum Pharmaceuticals

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Comerica Bank grew its stake in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at about $217,000. Finally, Empowered Funds LLC increased its stake in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares during the period.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.